Literature DB >> 27614712

Prognostic and pathophysiological marker for patients with chronic thromboembolic pulmonary hypertension: Usefulness of diffusing capacity for carbon monoxide at diagnosis.

Rika Suda1, Nobuhiro Tanabe1,2, Keiichi Ishida3, Fumiaki Kato1, Takashi Urushibara1, Ayumi Sekine1,2, Rintaro Nishimura1,2, Takayuki Jujo1,2, Toshihiko Sugiura1, Ayako Shigeta1, Seiichiro Sakao1, Koichiro Tatsumi1.   

Abstract

BACKGROUND AND
OBJECTIVE: Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease in some patients, despite improved treatments. Microvasculopathy has been implicated in the poor outcomes of patients with CTEPH. A reduction in the diffusing capacity for carbon monoxide (DLCO ) was previously suggested to indicate microvasculopathy in CTEPH patients; therefore, we assessed DLCO /alveolar ventilation (DLCO /VA ) as a prognostic and pathophysiological marker in CTEPH.
METHODS: We performed a retrospective cohort study of 214 CTEPH patients consecutively diagnosed between 1986 and 2011. After exclusion of 24 patients because of missing DLCO data or severe obstructive impairment, the mortality rates of medically treated patients classified with normal or decreased DLCO values were compared, and prognostic factors were determined. The relationship between long-term surgical outcomes and DLCO /VA was also investigated.
RESULTS: Ninety-one inoperable patients were treated medically, two of whom underwent balloon pulmonary angioplasty. Ninety-nine underwent pulmonary endarterectomy. The 5-year survival rate of medically treated patients was significantly lower in patients with decreased DLCO /VA than in those with normal values (61.4% vs 90.4%, P = 0.017). Decreased preoperative DLCO /VA was associated with a smaller percent decrease in post-operative pulmonary vascular resistance, but not with the extent of proximal thrombi; these results may support our hypothesis that DLCO reflects microvascular involvement.
CONCLUSION: Decreased DLCO /VA was associated with poor outcomes of medically treated CTEPH patients; and may be useful for identifying high-risk patients, potentially leading to earlier and more appropriate interventions.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  chronic thromboembolic pulmonary hypertension; pulmonary diffusing capacity; pulmonary embolism; pulmonary function tests; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27614712     DOI: 10.1111/resp.12883

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  9 in total

1.  Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Yu Taniguchi; Philippe Brenot; Xavier Jais; Carlos Garcia; Jason Weatherald; Olivier Planche; Elie Fadel; Marc Humbert; Gérald Simonneau
Journal:  Chest       Date:  2018-05-03       Impact factor: 9.410

2.  Characteristics of Japanese elderly patients with pulmonary arterial hypertension.

Authors:  Yukiko Takahashi; Keiko Yamamoto; Nobuhiro Tanabe; Rika Suda; Ken Koshikawa; Yumiko Ikubo; Eiko Suzuki; Hiroki Shoji; Akira Naito; Hajime Kasai; Rintaro Nishimura; Takayuki Jujo Sanada; Toshihiko Sugiura; Ayako Shigeta; Seiichiro Sakao; Koichiro Tatsumi
Journal:  Pulm Circ       Date:  2020-10-27       Impact factor: 3.017

3.  Preoperative pulmonary function correlates with systemic inflammatory response and prognosis in patients with non-small cell lung cancer: results of a single-institution retrospective study.

Authors:  Yongyin Gao; Hongdian Zhang; Yue Li; Dandan Wang; Yinlu Ma; Qing Chen
Journal:  Oncotarget       Date:  2017-04-18

4.  Factors predicting outcome after pulmonary endarterectomy.

Authors:  Cécile Tromeur; Xavier Jaïs; Olaf Mercier; Francis Couturaud; David Montani; Laurent Savale; Mitja Jevnikar; Jason Weatherald; Olivier Sitbon; Florence Parent; Dominique Fabre; Sacha Mussot; Philippe Dartevelle; Marc Humbert; Gérald Simonneau; Elie Fadel
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

5.  The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.

Authors:  Yukiko Takahashi; Keiko Yamamoto; Seiichiro Sakao; Takao Takeuchi; Rika Suda; Nobuhiro Tanabe; Koichiro Tatsumi
Journal:  BMC Pulm Med       Date:  2021-03-16       Impact factor: 3.317

6.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

7.  Diffusing Capacity for Carbon Monoxide Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Xin Li; Yi Zhang; Qin Luo; Qing Zhao; Qixian Zeng; Tao Yang; Qi Jin; Lu Yan; Anqi Duan; Jiaran Liu; Chenhong An; Xiuping Ma; Changming Xiong; Zhihui Zhao; Zhihong Liu
Journal:  Front Cardiovasc Med       Date:  2021-12-02

8.  Microvasculopathy Evaluated by Dual-Energy Computed Tomography in Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension.

Authors:  Keisuke Miwa; Yu Taniguchi; Hiroyuki Fujii; Yoichiro Matsuoka; Hiroyuki Onishi; Kenichi Yanaka; Yu Izawa; Yasunori Tsuboi; Atsushi Kono; Noriaki Emoto; Kenichi Hirata
Journal:  Life (Basel)       Date:  2022-08-15

9.  The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension.

Authors:  Stefan Stadler; Nicoletta Mergenthaler; Tobias J Lange
Journal:  Pulm Circ       Date:  2019-12-27       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.